In this study, we describe our experience with the compassionate use of sorafenib in patients with advanced RCC. Many of these patients would not have qualified for enrollment into a standard ...

Sorafenib, a multiprotein kinase inhibitor, has been shown to have antitumor activity in renal adenocarcinoma animal models and to prolong survival in patients with metastatic RCC. In a phase III ...

(n = 65) Randomized, discontinuation trial (part 2 of a two-part trial) Sorafenib Placebo Rate of progression-free survival 12 wk after randomization: 50% (sorafenib) vs. 18% (placebo) (p = 0.0077 ...

Formation and function of skeletal muscle fibers impaired Sorafenib is used for liver cell carcinoma (HCC) and renal cell carcinoma (RCC), among others. The chemotherapeutic agent belongs to the ...

Today, the majority of patients with metastatic RCC will be treated with a TKI—either with the FDA-approved agents sorafenib and sunitinib, or with one of the plethora of current investigational ...

as a first-line treatment for patients with advanced RCC. The drug is approved for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib ...